Northstrive Biosciences公司已正式签署一项最终许可协议,旨在推动其创新产品El-22与El-32的商业化应用。这两种产品是基于肌肉抑制素(Myostatin)工程改造的益生菌,专门用于动物健康领域的肌肉维持,标志着该技术在畜牧与伴侣动物营养管理方面迈出关键一步。
Northstrive Biosciences公司已正式签署一项最终许可协议,旨在推动其创新产品El-22与El-32的商业化应用。这两种产品是基于肌肉抑制素(Myostatin)工程改造的益生菌,专门用于动物健康领域的肌肉维持,标志着该技术在畜牧与伴侣动物营养管理方面迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.